<DOC>
	<DOCNO>NCT00578305</DOCNO>
	<brief_summary>This 3 arm study assess efficacy rituximab ( MabThera®/Rituxan® ) prevention progression structural joint damage participant active rheumatoid arthritis inadequate clinical response methotrexate . Participants randomize receive rituximab 500 mg intravenously ( iv ) , rituximab 1000 mg iv , placebo iv day 1 15 every 24 week main study ; participant receive concomitant methotrexate stable dose 12.5-25 mg/week throughout study . Further course rituximab provide eligible participant . Structural joint damage assess magnetic resonance imaging ( MRI ) baseline interval study .</brief_summary>
	<brief_title>A Study Rituximab ( MabThera®/Rituxan® ) Patients With Rheumatoid Arthritis Inadequate Response Methotrexate</brief_title>
	<detailed_description>There 3 phase study : A 52 week long main study , study extension phase , 48 week long safety follow-up phase . The first course treatment placebo rituximab initiate Day 1 52 week long main study . A second course treatment initiate Week 24 , participant meet eligibility criterion . After Week 52 , eligible participant receive treatment course interval ≥ 6 month study extension phase . No treatment administer safety follow-up phase . Participants meet follow eligibility criterion receive rituximab study extension phase . - Minimum 24 week pass since first infusion last course study medication . - C-reactive protein-based Disease Activity Score 28 ( DAS28-CRP ) ≥ 2.6 . - Absolute neutrophil count 1.5 x 103/μL . - Patient develop contraindication receive rituximab , : 1 . Any new uncontrolled concomitant disease , limited , cardiovascular disease , nervous system , pulmonary , renal , hepatic , endocrine gastrointestinal disorder . 2 . Primary secondary immunodeficiency ( history , currently active ) , include know history HIV infection . 3 . Known active infection kind ( exclude fungal infection nail bed ) , major episode infection require hospitalization , treatment iv anti-infectives within 4 week prior infusion completion oral anti-infectives within 2 week prior infusion . - Patient pregnant breast feeding . - Patients enter study find hepatitis B surface antigen ( HBsAg ) negative , hepatitis B core antibody ( HBcAb ) positive , negative hepatitis B viral DNA ( &lt; 29 IU/mL ) aspartate aminotransferase ( AST ) /alanine aminotransferase ( ALT ) ≤ 2.5 x upper limit normal ( ULN ) result within last 12 week .</detailed_description>
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
	<mesh_term>Prednisolone</mesh_term>
	<mesh_term>Folic Acid</mesh_term>
	<mesh_term>Vitamin B Complex</mesh_term>
	<mesh_term>Prednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone</mesh_term>
	<mesh_term>Prednisolone hemisuccinate</mesh_term>
	<mesh_term>Prednisolone phosphate</mesh_term>
	<criteria>Adult patient , 1880 year age . Active rheumatoid arthritis ≥ 3 month ≤ 10 year . Evidence erosive disease and/or clinical synovitis signal joint . Inadequate response 12.525 mg/week methotrexate ≥ 12 week . Rheumatic autoimmune disease inflammatory joint disease rheumatoid arthritis . Any surgical procedure within 12 week prior baseline . Previous treatment biologic agent B cell modulate cell deplete therapy .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>March 2015</verification_date>
</DOC>